These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 18074761

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador).
    Grossarth-Maticek R, Ziegler R.
    Forsch Komplementmed; 2006 Oct; 13(5):285-92. PubMed ID: 17057389
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis.
    Grossarth-Maticek R, Ziegler R.
    Eur J Med Res; 2006 Nov 30; 11(11):485-95. PubMed ID: 17182361
    [Abstract] [Full Text] [Related]

  • 5. Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador).
    Grossarth-Maticek R, Ziegler R.
    Forsch Komplementmed; 2007 Jun 30; 14(3):140-7. PubMed ID: 17596694
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with "well-established use".
    Bock PR, Friedel WE, Hanisch J, Karasmann M, Schneider B.
    Forsch Komplementarmed Klass Naturheilkd; 2004 Aug 30; 11 Suppl 1():23-9. PubMed ID: 15353899
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Immune modulation using mistletoe (Viscum album L.) extracts Iscador.
    Büssing A.
    Arzneimittelforschung; 2006 Jun 30; 56(6A):508-15. PubMed ID: 16927532
    [Abstract] [Full Text] [Related]

  • 17. Absence of tumor growth stimulation in a panel of 26 human tumor cell lines by mistletoe (Viscum album L.) extracts Iscador in vitro.
    Kelter G, Fiebig HH.
    Arzneimittelforschung; 2006 Jun 30; 56(6A):435-40. PubMed ID: 16927523
    [Abstract] [Full Text] [Related]

  • 18. Viscotoxins, mistletoe lectins and their isoforms in mistletoe (Viscum album L.) extracts Iscador.
    Urech K, Schaller G, Jäggy C.
    Arzneimittelforschung; 2006 Jun 30; 56(6A):428-34. PubMed ID: 16927522
    [Abstract] [Full Text] [Related]

  • 19. Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer.
    Matthes H, Friedel WE, Bock PR, Zänker KS.
    Curr Mol Med; 2010 Jun 30; 10(4):430-9. PubMed ID: 20455850
    [Abstract] [Full Text] [Related]

  • 20. [What prospects of success does Iscador therapy offer in advanced ovarian cancer?].
    Hassauer W, Gutsch J, Burkhardt R.
    Onkologie; 1979 Feb 30; 2(1):28-36. PubMed ID: 392367
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.